Comprehensive Insurance Coverage is Critical to Stemming Opioid Crisis

Addiction Experts Oppose BCRA

Our nation’s escalating opioid crisis – with more than 144 people dying every day from overdose – will not abate without access to comprehensive substance use disorder treatment in private insurance and Medicaid. The Senate’s version of healthcare repeal would cripple national efforts to address this public health epidemic.

No time-limited infusion of federal dollars for addiction treatment can fill the gaping coverage and financing holes, meet the unmet need for substance use treatment, or prevent the significant disruption in health care delivery that will result under the enactment of the Better Care Reconciliation Act (BCRA).

Research has clearly shown that substance use disorders are complex, chronic medical conditions, best treated with comprehensive and integrated care. Until the passage of the Affordable Care Act, substance use disorders were financed and treated separately from the rest of healthcare, largely through government funded block grants. This produced a truly segregated, seriously under-resourced system that contributed to the current addiction epidemic in this country and perpetuated discrimination.

Separate funding to address the opioid crisis will not meet the overarching healthcare needs of patients struggling with addiction, who often have numerous co-occurring health problems that must also be addressed. It will not adequately support prevention for SUDs, nor the long-term recovery management that is indicated for chronic medical illnesses.

The non-partisan Congressional Budget Office estimates that BCRA would cut Medicaid funding by $772 billion, as the bill would impose caps on federal Medicaid funds and end the Medicaid expansion. These changes would mean that millions of people with substance use disorders would lose coverage for lifesaving treatment. Approximately half of Medicaid enrollees have substance use or mental health disorders, and Medicaid pays for approximately 30% of the cost of medications to treat addiction. Countless people who are currently in treatment and on the road to recovery would lose access to the critical services needed to maintain their health. The rate of opioid fatality would sharply rise.

The BCRA will end significant progress in creating a stable and sustainable financing structure for substance use treatment through Medicaid and private insurance, stripping away addiction coverage from millions of Americans who desperately need it. Further, it would reinstate discriminatory coverage of substance use treatment by allowing states to waive such benefits in Essential Health Benefit-based plans and reinstate underwriting for pre-existing conditions making coverage for addiction treatment unaffordable for many Americans.
The Senate healthcare repeal plan, which would leave 22 million Americans uninsured, is untenable. It will be particularly devastating to millions of Americans who have complex or pre-existing conditions, including substance use disorders. If enacted, the BCRA would undercut our national efforts to stem the opioid crisis, dramatically cutting funding for critical life-saving treatments.

The undersigned individuals and institutions represent leaders in the field of addiction care, research and policy. **We urge Congress to reject this harmful legislation. The devastation caused by the Senate bill will not be ameliorated by a short-term infusion of grant funding to address the opioid epidemic.**

Paul Samuels, JD  
President/Director  
Legal Action Center

Marcia Lee Taylor  
Chief Policy Officer  
Partnership for Drug-Free Kids

Michael Botticelli  
Executive Director, Grayken Center for Addiction Medicine  
Boston Medical Center  
Former Director, White House Office of National Drug Control Policy

Ronald Manderscheid  
Executive Director  
NACBHDD - National Association of County Behavioral Health and Developmental Disability Directors  
NARMH - National Association for Rural Mental Health

Patty McCarthy Metcalf  
Executive Director  
Faces & Voices of Recovery

Mark W. Parrino, M.P.A.  
President  
American Association for the Treatment of Opioid Dependence (AATOD)

Susan P. Brown  
Vice President and Secretary-Treasurer; Director of Finance and Administration  
The National Center on Addiction and Substance Abuse

A. Thomas McLellan, PhD  
Founder, Treatment Research Institute  
Former Deputy Director, White House Office of National Drug Control Policy

Chuck Ingoglia  
Sr. Vice President, Public Policy and Practice Improvement  
National Council for Behavioral Health

Alice Dembner  
Program Director, Substance Use Disorders and Justice-Involved Populations  
Community Catalyst

Kelly J. Clark, MD, MBA,  
President  
American Society of Addiction Medicine

Grant Smith  
Deputy Director  
National Affairs of the Drug Policy Alliance
Kathryn Cates-Wessel
CEO
American Academy of Addiction Psychiatry

Roberta Carlin, M.S., J.D
Executive Director
American Association on Health and Disability

Daniel Raymond
Deputy Director of Planning and Policy, Harm Reduction Coalition

Gary Mendell
Founder and CEO
Shatterproof

Jim Hood, Co-Founder and CEO
Greg Williams, Co-Founder and EVP
Facing Addiction

Cynthia Moreno Tuohy, NCAC II, CDC III, SAP
Executive Director
NAADAC, the Association for Addiction Professionals

Emalie Huriaux, MPH
Director of Federal & State Affairs, Project Inform
Chair, California Hepatitis Alliance

Robert Heimer, PhD
Professor of Epidemiology, Yale School of Public Health
Center for Interdisciplinary Research on AIDS

Pamela F. Rodriguez
President & CEO
TASC, Inc. (Treatment Alternatives for Safe Communities)

Shira Shavit, MD
Executive Director, Transitions Clinic Network
Associate Clinical Professor, UCSF

Hollis Pickett
President
Local Area Support For Hepatitis (LASH)

Derek Hodel
Interim Executive Director
Drug Policy Alliance

Wendy Armstrong, MD
Chair of the Board, HIV Medicine Association

Wayne Wirta
President/CEO
NCADD-NJ

Tim Clement
Senior Policy Advisor
The Kennedy Forum

Justin Luke Riley
President
Young People in Recovery
Nancy Rosen Cohen  
Executive Director, Maryland Chapter  
National Council on Alcoholism and Drug Dependence

Alison Oliveto, Ph.D.  
Program Director, Clinical Trials Innovation Unit  
Translational Research Institute  
Professor and Vice Chair for Research  
Psychiatry and Behavioral Sciences  
Director, Center for Addiction Research  
University of Arkansas for Medical Sciences

David C. Perlman, MD  
Professor of Medicine and Chief, Infectious Diseases, Icahn School of Medicine at Mount Sinai  
Chief, Infectious Diseases, Mount Sinai Beth Israel

Richard Hawks, PhD  
Deputy Director, Division of Treatment Research and Development, Retired  
National Institute on Drug Abuse, NIH

Avik Chatterjee, MD  
Physician, Boston Health Care for the Homeless Program  
Instructor, Harvard Medical School

Scott Burris  
Professor and Director  
Center for Public Health Law Research  
Temple University Beasley School of Law

Hannah Watson MD  
Maternal Child and Reproductive Health Fellow  
University of New Mexico Hospital

Thomas Miller  
President  
Association for Ambulatory Behavioral Healthcare

Jason Grebely BSc PhD  
Associate Professor  
Kirby Institute, UNSW Australia  
NHMRC Career Development Fellow  
President  
International Network on Hepatitis in Substance Users (INHSU)

Henry R. Kranzler, M.D.  
Professor of Psychiatry  
Director, Center for Studies of Addiction  
University of Pennsylvania  
Perelman School of Medicine

Marguerite Beiser, ANP-BC  
Director of HCV Services  
Boston Health Care for the Homeless Program

Lois Petty  
SEP Site Manager  
SLO Bangers Syringe Exchange and Overdose Prevention Program

Amanda Latimore, PhD  
Director of Social Epidemiology and Evaluation Behavioral Health System Baltimore

Adam Brooks, PhD  
Director, Treatment Research Institute  
Public Health Management Corporation
Keith Brown, MPH  
Director, Health & Harm Reduction  
Katal Center for Health, Equity, and Justice

Paul Pentel  
Director, Division of Clinical Pharmacology  
Hennepin County Medical Center

Jerry Douglas MD  
Chief Medical Officer  
Hillside Health Center

Matt Slonaker, JD  
Executive Director  
Utah Health Policy Project

Bruce G. Trigg, MD  
Addiction medicine and public health consultant

Annie Herriott, M.S., MSW  
Doctoral Candidate  
Boston University School of Social Work

Tom Coderre  
Senior Advisor  
Altarum Institute

Orlando Chavez  
Health Systems Navigator, HIV/HepC Prevention and Harm Reduction Services  
GLIDE

Cyndee Clay  
Executive Director  
HIPS

Elizabeth Spradley,  
Nurse  
Johns Hopkins Hospital

Victor Capoccia  
Former Team Leader, Addiction Prevention and Treatment  
Robert Wood Johnson Foundation

Brendan Saloner, PhD  
Assistant Professor of Health Policy and Management,  
John Hopkins Bloomberg School of Public Health  
(on behalf of self, not institution)

Kathleen O'Brien, PhD  
President  
The Maryland Addictions Directors Council

Jo L. Sotheran, PhD  
MARS Project